US EditionPublished • loading... • Updated
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
Summary by Alpha-1 Foundation
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD
“This is exciting news for the Alpha-1 community, marking an important regulatory milestone for Tessera Therapeutics and also, in the field of in vivo genome editing. It is the first-ever IND clearance for a therapy based on target-primed reverse transcription (TPRT)-based genome editing. This approval allows Tessera to initiate its Phase 1/2 clinical trial, bringing the company closer to delivering an innovative therapy designed to permanen…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
